>>Countdown to our free event: Meet the Real Money Pros: Market Strategies for 2012NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS Abercrombie & Fitch ( ANF) cut from Conviction Buy List at Goldman. Valuation call, as the stock is up 32% over the past 11 months. Aeropostale ( ARO) upgraded at Goldman from Sell to Neutral. The company can expand margins in the coming quarter. Amedisys ( AMED) downgraded to sell at TheStreet Ratings. American Tower ( AMT) numbers adjusted at Citigroup. Shares of AMT now seen reaching $65. Estimates lowered on FX headwinds. Buy rating. American Tower estimates, target raised at JP Morgan. Shares of AMT now seen reaching $62. Estimates also increased on Core and Sprint MLA. AmerisourceBergen ( ABC) estimates increased at UBS. ABC estimates increased through 2013. Positive operating trends. Maintain $47 price target and Buy rating. Ann ( ANN) downgraded at Goldman from Neutral to Sell. Margins are peaking and the company is leveraged to slower macro growth. Archer Daniels Midland ( ADM) numbers cut at Morgan Stanley. Shares of ADM now seen reaching $37. Estimates also reduced, given lower oilseed margins. Overweight rating. Atmel ( ATML) downgraded at Needham from Strong Buy to Buy. Company could face inventory rebalancing in the next couple of quarters. Atmel upgraded to buy at TheStreet Ratings. Autodesk ( ADSK) target cut at UBS to $43. VARs continue to plod through a sluggish economic environment. Buy rating. Baker Hughes ( BHI) numbers cut at Credit Suisse. Shares of BHI now seen reaching $80. Estimates also reduced, given lower expected North American pricing. Outperform rating. Baker Hughes estimates increased at Sterne Agee. BHI estimates raised through 2012. Bullish rig count forecast. Maintain $71 price target and Buy rating. Baker Hughes estimates, target cut at UBS. Shares of BHI now seen reaching $82. Estimates also increased as overall story is still in on track despite a sloppy 3Q. Buy rating. Catalyst Health ( CHSI) numbers lowered at Credit Suisse. Shares of CHSI now seen reaching $62. Estimates also cut, to match the company's new guidance. Outperform rating. Caterpillar ( CAT) rated new Overweight at Morgan Stanley. Valuation call, based on a $125 price target. CME Group ( CME) numbers lowered at Jefferies. CME estimates were cut through 2012. Volume has moderates and expenses could be back on the rise. Buy rating and new $297 price target. CME Group estimates lowered at UBS through 2012. MF Global bankruptcy may be a blow to the futures industry as a whole. Buy rating.
Corning ( GLW) downgraded at JP Morgan from Neutral to Underweight. Consumer risks are mounting.Deere ( DE) rated new Underweight at Morgan Stanley. Company faces slower growth and margin pressures. $74 price target. Diamond Foods ( DMND) downgraded at BofA/Merrill from Buy to Neutral. $65 price target. Estimates also cut, as the Pringles acquisition has been delayed. Discovery Communications ( DISCA) numbers increased at UBS. Shares of DISCA now seen reaching $43. Estimates also raised as Netflix deal more accretive than expectations. Neutral rating. Emerson Electric ( EMR) target increased at UBS to $51. Positive outlook despite challenging macro. Maintain Neutral rating. Emerson Electric estimates, target cut at Sterne Agee. Shares of EMR now seen reaching $54. Estimates also lowered on slower expected global growth. Neutral rating. EOG Resources ( EOG) estimates increased at UBS through 2012. 3Q beats on higher than expected natural gas and NGL production. Neutral rating. Fidelity ( FIS) estimates, target lowered at Oppenheimer. FIS estimates were cut through 2012. EBITDA growth is slowing. Outperform rating and new $32 price target. FXCM ( FXCM) upgraded at Citigroup from Sell to Neutral. $11.25 price target. With the recent downdraft we see a more balanced risk/reward. HCA ( HCA) estimates, target raised at Credit Suisse. Shares of HCA now seen reaching $27, according to Credit Suisse. Estimates also increased, given solid volume growth and cost cuts. Outperform rating. Impax Laboratories ( IPXL) numbers cut at Goldman. Shares of IPXL now seen reaching $18. Estimates also reduced, given lower expected Adderall XR sales. Sell rating. Intrepid Potash ( IPI) rated new Neutral at UBS. $28 price target. Significant growth, but at a fair price. IPG Photonics ( IPGP) upgraded at Needham from Hold to Buy. $60 price target. Company has solid visibility. Lamar Advertising ( LAMR) numbers cut at Benchmark. Shares of LAMR now seen reaching $18. Estimates also reduced, as the outdoor advertising market has stalled. Hold rating. MEMC Electronic Materials ( WFR) numbers lowered at Citigroup. Shares of WFR now seen reaching $10. Estimates also lowered on softer wafer volumes/pricing. Buy rating.
Twitter and become a fan on Facebook.